retatrutide osteoarthritis Once-Weekly Reduces Weight and Knee Pain in Patients With Obesity and First phase 3 data for
Description
Injection-site reactions (redness, itching, swelling) affects between 1-3% of user and mild rashes occur in 1-3% of users
Not only is it groundbreaking in its capacity to regulate glucose levels, but it also massively supports weight loss
Depression was the most commonly reported psychiatric adverse event (50.3% of psychiatric reports), followed by anxiety (38.7%) and suicidal ideation (19.6%)
Specific variants in these pathways can influence receptor sensitivity, medication clearance, and side effect susceptibility
